NCT03427359View on ClinicalTrials.gov

Induction Cisplatin and Capecitabine Followed by Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

January 22, 2015

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG

cisplatin, capecitabine

Experimental arm patients received 3 cycles of induction chemotherapy (cisplatin 80mg/m2, day 1; oral capecitabine 1000mg/m2 twice daily from day1-14, repeated every 3 weeks) followed by concomitant cisplatin (100mg/m2,day1,every 3 weeks) for a total of 2 cycles with radiotherapy.

All Listed Sponsors
lead

The University of Hong Kong-Shenzhen Hospital

OTHER

NCT03427359 - Induction Cisplatin and Capecitabine Followed by Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma | Biotech Hunter | Biotech Hunter